Publication: In vitro cytochrome P450 (CYP)- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort (6β-OH-21-desDFZ): A major human metabolite of deflazacort
This research article, published in Pharmacology Research & Perspectives, evaluates CYP-and transporter-mediated drug interaction potentials of 6β-OH-21-desDFZ
Learn more about the pharmacokinetic drug interaction potential of 6 β-OH-21-desDFZ, a major circulating but not biologically active metabolite of deflazacort (DFZ)
The in vitro CYP- and transporter-mediated drug interaction potentials of 6β-OH-21-desDFZ is systematically evaluated
A novel approach to preparing radioactively labeled 14C-6β-OH-21-desDFZ using microbial biotransformation for transporter substrate assay is also presented
Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.
Ma J, Beers B, Manohar R, et al. Pharmacol Res Perspect. 2021;9:e00748
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2300008 | March 2023
Sign in or register to access exclusive content on this site